Avalo Therapeutics Inc.
AVTX | NASDAQ
$16.17
-$0.40 (-2.41%)
At close: Sep 21, 2026, 4:00 PM ET
$16.17
$0 (0.00%)
After-hours:
Sep 21, 2026, 7:30 PM ET
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | 59K | 441K | 1.92M | 18.05M | 5.4M | 6.7M |
Cost of Revenue | n/a | -366K | 1.28M | 3.43M | 1.49M | 300K |
Gross Profit | 59K | 807K | 640K | 14.62M | 3.91M | 6.4M |
Operating Income | -72.93M | -68.51M | -27.35M | -37.44M | -82.13M | n/a |
Interest Income | 4.35M | 3.32M | n/a | n/a | n/a | 49K |
Pretax Income | -78.09M | -35.02M | -31.53M | -41.63M | -84.55M | -67.18M |
Net Income | -78.26M | -35.13M | -31.54M | -41.66M | -84.38M | -63.5M |
Selling & General & Admin | 22.9M | 17.24M | 10.3M | 20.71M | 24.66M | 19.76M |
Research & Development | 50.08M | 52.08M | 13.78M | 31.31M | 59.84M | 32.19M |
Other Expenses | n/a | n/a | 3.91M | 38K | 1.55M | -45.55M |
Operating Expenses | 72.98M | 69.32M | 27.99M | 52.06M | 86.04M | 6.4M |
Interest Expense | n/a | n/a | 3.42M | 4.17M | 2.39M | n/a |
Selling & Marketing Expenses | 470K | 789K | 33K | 76K | 1.66M | 2.34M |
Cost & Expenses | 72.98M | 68.95M | 29.28M | 55.49M | 87.53M | 6.7M |
Income Tax Expense | 165K | 114K | 14K | 28K | -196K | -2.79M |
Shares Outstanding (Basic) | 13.4M | 8.13M | 277.73K | 39.2K | 36.19K | 25.51K |
Shares Outstanding (Diluted) | 13.4M | 10.78M | 277.73K | 39.2K | 36.19K | 25.51K |
EPS (Basic) | -5.84 | -4.32 | -113.58 | -1.06K | -2.33K | -2.52K |
EPS (Diluted) | -5.84 | -3.26 | -113.58 | -1.06K | -2.33K | -2.52K |
EBITDA | -77.75M | -34.85M | -23.29M | -37.29M | -80.5M | -45.45M |
EBIT | -78.09M | -35.02M | -23.44M | -37.46M | -82.15M | -47.29M |
Depreciation & Amortization | 344K | 169K | 158K | 166K | 1.66M | 1.84M |
Add to Watchlist
Select watchlists to add or remove AVTX